In a phase 2 study, patients with metastatic urothelial carcinoma who had stable disease on first-line platinum-based chemotherapy experienced a delay in disease progression when switched to ...

Sarcomas, a diverse group of malignancies, exhibit substantial heterogeneity in both biological behavior and microenvironment, influencing their response to immunotherapy. Although pembrolizumab is ...

Against the backdrop of a case report, pembrolizumab was investigated as immunotherapy for undifferentiated pleomorphic soft tissue sarcoma. Noting that immunotherapy for soft tissue sarcoma (STS) has ...

A clinical trial shows that combining laser heat therapy with immunotherapy significantly extends the lives of patients with aggressive, recurrent brain cancer.

The addition of pembrolizumab to chemotherapy in high-risk early triple-negative breast cancer (TNBC) improves cancer outcomes. However, pembrolizumab induces varied immune-related adverse events ...

Please provide your email address to receive an email when new articles are posted on . First phase 3 study to show a survival benefit with adjuvant therapy in kidney cancer. Adjuvant pembrolizumab ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

HealthDay News — For patients with asthma, receipt of immune checkpoint inhibitor (ICI) therapy for melanoma or renal cell carcinoma is not associated with an increased risk for exacerbations, ...

Synthekine Inc., an engineered cytokine therapeutics company, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute “This approval is significant for ...